Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant
Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition...
Saved in:
| Published in: | Journal of oncology pharmacy practice Vol. 26; no. 4; p. 809 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01.06.2020
|
| Subjects: | |
| ISSN: | 1477-092X, 1477-092X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition may result in increased concentrations of vincristine and an increased incidence of toxicity.
The primary objective of this study was to investigate if there is a clinically significant drug interaction between vincristine and aprepitant or fosaprepitant resulting in early-onset peripheral neuropathy. The secondary objective of this study was to investigate the cumulative rate of chemotherapy-induced peripheral neuropathy (CIPN).
This was a single-centered, retrospective, cohort chart review. Patients receiving vincristine-based chemotherapy between 1 July 2010 through 30 June 2018 were identified and reviewed for concomitant use of aprepitant or fosaprepitant and incidence of neuropathy. Early-onset CIPN was defined as neuropathy onset during the first cycle of chemotherapy.
A total of 115 subjects were retrospectively reviewed over the study period, of whom 71 were included in the aprepitant/fosaprepitant group and 44 were included in the group without a NK-1 receptor antagonist. Of the subjects who received aprepitant/fosaprepitant, 26.7% experienced early-onset peripheral neuropathy as compared to 22.7% in the group without a NK-1 receptor antagonist (
= 0.627). Overall, CIPN was higher in the group who received aprepitant/fosaprepitant compared to the group without (56% vs. 36%,
= 0.036).
There appears to be an increased risk of CIPN with the concomitant use of vincristine and aprepitant or fosaprepitant. |
|---|---|
| AbstractList | Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition may result in increased concentrations of vincristine and an increased incidence of toxicity.BACKGROUNDPeripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition may result in increased concentrations of vincristine and an increased incidence of toxicity.The primary objective of this study was to investigate if there is a clinically significant drug interaction between vincristine and aprepitant or fosaprepitant resulting in early-onset peripheral neuropathy. The secondary objective of this study was to investigate the cumulative rate of chemotherapy-induced peripheral neuropathy (CIPN).OBJECTIVEThe primary objective of this study was to investigate if there is a clinically significant drug interaction between vincristine and aprepitant or fosaprepitant resulting in early-onset peripheral neuropathy. The secondary objective of this study was to investigate the cumulative rate of chemotherapy-induced peripheral neuropathy (CIPN).This was a single-centered, retrospective, cohort chart review. Patients receiving vincristine-based chemotherapy between 1 July 2010 through 30 June 2018 were identified and reviewed for concomitant use of aprepitant or fosaprepitant and incidence of neuropathy. Early-onset CIPN was defined as neuropathy onset during the first cycle of chemotherapy.METHODOLOGYThis was a single-centered, retrospective, cohort chart review. Patients receiving vincristine-based chemotherapy between 1 July 2010 through 30 June 2018 were identified and reviewed for concomitant use of aprepitant or fosaprepitant and incidence of neuropathy. Early-onset CIPN was defined as neuropathy onset during the first cycle of chemotherapy.A total of 115 subjects were retrospectively reviewed over the study period, of whom 71 were included in the aprepitant/fosaprepitant group and 44 were included in the group without a NK-1 receptor antagonist. Of the subjects who received aprepitant/fosaprepitant, 26.7% experienced early-onset peripheral neuropathy as compared to 22.7% in the group without a NK-1 receptor antagonist (P = 0.627). Overall, CIPN was higher in the group who received aprepitant/fosaprepitant compared to the group without (56% vs. 36%, P = 0.036).RESULTSA total of 115 subjects were retrospectively reviewed over the study period, of whom 71 were included in the aprepitant/fosaprepitant group and 44 were included in the group without a NK-1 receptor antagonist. Of the subjects who received aprepitant/fosaprepitant, 26.7% experienced early-onset peripheral neuropathy as compared to 22.7% in the group without a NK-1 receptor antagonist (P = 0.627). Overall, CIPN was higher in the group who received aprepitant/fosaprepitant compared to the group without (56% vs. 36%, P = 0.036).There appears to be an increased risk of CIPN with the concomitant use of vincristine and aprepitant or fosaprepitant.CONCLUSIONThere appears to be an increased risk of CIPN with the concomitant use of vincristine and aprepitant or fosaprepitant. Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition may result in increased concentrations of vincristine and an increased incidence of toxicity. The primary objective of this study was to investigate if there is a clinically significant drug interaction between vincristine and aprepitant or fosaprepitant resulting in early-onset peripheral neuropathy. The secondary objective of this study was to investigate the cumulative rate of chemotherapy-induced peripheral neuropathy (CIPN). This was a single-centered, retrospective, cohort chart review. Patients receiving vincristine-based chemotherapy between 1 July 2010 through 30 June 2018 were identified and reviewed for concomitant use of aprepitant or fosaprepitant and incidence of neuropathy. Early-onset CIPN was defined as neuropathy onset during the first cycle of chemotherapy. A total of 115 subjects were retrospectively reviewed over the study period, of whom 71 were included in the aprepitant/fosaprepitant group and 44 were included in the group without a NK-1 receptor antagonist. Of the subjects who received aprepitant/fosaprepitant, 26.7% experienced early-onset peripheral neuropathy as compared to 22.7% in the group without a NK-1 receptor antagonist ( = 0.627). Overall, CIPN was higher in the group who received aprepitant/fosaprepitant compared to the group without (56% vs. 36%, = 0.036). There appears to be an increased risk of CIPN with the concomitant use of vincristine and aprepitant or fosaprepitant. |
| Author | Edwards, Jessi K Bossaer, John B Lewis, Paul O Sant, Ashley |
| Author_xml | – sequence: 1 givenname: Jessi K surname: Edwards fullname: Edwards, Jessi K organization: HCA TriStar Centennial Medical Center, Nashville, TN, USA – sequence: 2 givenname: John B orcidid: 0000-0002-6096-9687 surname: Bossaer fullname: Bossaer, John B organization: Bill Gatton College of Pharmacy, East Tennessee St. University, Johnson City, TN, USA – sequence: 3 givenname: Paul O surname: Lewis fullname: Lewis, Paul O organization: Department of Infectious Diseases, Johnson City Medical Center, Johnson City, TN, USA – sequence: 4 givenname: Ashley surname: Sant fullname: Sant, Ashley organization: Department of Oncology, Johnson City Medical Center, Johnson City, TN, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31446866$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LxDAQxYOsuB969yS56aVukqZJepRFXWFBDwreSpKm22ib1iRV97-36IpeZn6PebwHMwcT1zkDwClGlxhzvsSIC5xlBOeCI0HRAZhhynmCcvI8-cdTMA_hBSEkOBFHYJpiSplgbAY-H4y3fW28bKAzg-96GesdtA6OVcm6K7ev1p0H2Ozavu5aCce7NS4G6I029t26LRyH9jZE6wz8sLGG0pXf0A0Ryt6b3kbp4rLqwp86BoeVbII52e8FeLq5flytk8397d3qapPoNOUxEWVKmFS44txIkVEttEKS5pQLzhjOtORUk0xwpXJFS8pKwVKOqxQZRZVWZAEufnJ7370NJsSitUGbppHOdEMoCBEoS3OO2Gg921sH1Zqy6L1tpd8Vv98iX_0gcX8 |
| CitedBy_id | crossref_primary_10_1007_s10549_025_07674_x crossref_primary_10_1177_10781552221079786 crossref_primary_10_1016_j_intimp_2023_110046 crossref_primary_10_2147_PGPM_S460878 crossref_primary_10_3390_encyclopedia4010031 crossref_primary_10_3390_cancers12092682 crossref_primary_10_1016_j_jtos_2021_06_007 crossref_primary_10_3390_life14111500 crossref_primary_10_1016_j_ejon_2024_102540 crossref_primary_10_3390_ijms22084112 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1177/1078155219870840 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1477-092X |
| ExternalDocumentID | 31446866 |
| Genre | Journal Article |
| GroupedDBID | --- -TM .2E .2F .2G .2J .2N 01A 0R~ 18M 1~K 29L 31R 31S 31U 31X 31Y 31Z 36B 4.4 53G 54M 5GY 5VS 6PF 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8R4 8R5 AABMB AACKU AACMV AACTG AADUE AAEWN AAGGD AAGMC AAJIQ AAJOX AAJPV AAJQC AAKGS AANSI AAPEO AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAWTL AAXOT AAYTG AAZBJ ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABHQH ABJNI ABKRH ABLUO ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACIWK ACJER ACJTF ACLFY ACLHI ACLZU ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADTBJ ADUKL ADVBO ADYCS ADZZY AECGH AECVZ AEDTQ AEKYL AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFRAH AFUIA AFWMB AGHKR AGKLV AGNHF AGPXR AGWFA AGWNL AHBZF AHDMH AHHFK AHMBA AIEWD AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV ASPBG AUTPY AUVAJ AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKEYQ BKIIM BKSCU BMSDO BPACV BPHCQ BSEHC BVXVI BWJAD C45 CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK DB0 DC- DC. DC0 DD- DD0 DE- DF. DF0 DO- DOPDO DV7 DV9 DWQXO D~Y EBS EJD EX3 F5P FEDTE FHBDP FYUFA GNUQQ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GUQSH H13 HF~ HMCUK HVGLF HZ~ J5H J8X K.F K.J M1P M2O M4V N9A NAPCQ NPM O9- OVD P.B P2P PADUT PHGZT PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM TEORI UKHRP WOW ZONMY ZPPRI ZRKOI ZSSAH 7X8 AAPII ABIDT ABJZC ADEBD AJGYC AJHME AJVBE SASJQ |
| ID | FETCH-LOGICAL-c337t-8d326ab1f77ea854c8cb0a4947876615ca74c2587bb9b4d46d86371f30eb4bcb2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000483674700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-092X |
| IngestDate | Thu Oct 02 10:26:51 EDT 2025 Thu Apr 03 07:07:02 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Aprepitant neuropathy vincristine fosaprepitant drug interaction |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c337t-8d326ab1f77ea854c8cb0a4947876615ca74c2587bb9b4d46d86371f30eb4bcb2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-6096-9687 |
| PMID | 31446866 |
| PQID | 2280539706 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2280539706 pubmed_primary_31446866 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Jun 20200601 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-Jun |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of oncology pharmacy practice |
| PublicationTitleAlternate | J Oncol Pharm Pract |
| PublicationYear | 2020 |
| SSID | ssj0008728 |
| Score | 2.2484145 |
| Snippet | Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 809 |
| Title | Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31446866 https://www.proquest.com/docview/2280539706 |
| Volume | 26 |
| WOSCitedRecordID | wos000483674700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA5uiBf3fSGC6MVgl7RJTiKieHHoQWFuQ7NUBjUd7SjOv_e9TKUnQfAS2kIhpF_f-_Je-32EnJi0Sqoqj5iBBMAg42cMyJFmnGujlLVKKB3MJkSvJ_t9VbQFt6b9rPInJoZAbWuDNfILlG3JIHlG-eXojaFrFHZXWwuNWTKfApVBVIt-pxYuRfBWjbkQLFJJv2tTQrAQEtXHcM8dSR79TjBDorld-e8UV8lySzHp1RQTa2TG-XWyeN820dfJaTGVq56c04fu76vmnJ7SohOynmyQrwLgGWQHXmjQvUT74gkdeuprz-5q-_Q89GcNfZkAJOrXkrYirQ2FMOqGWKqgMJgQR7yjWPOlpbfhoP4Y03L07tC1xI8vqrrpzjbJ4-3Nw_Uda50amElTMWbSAgssdVwJ4UqZcSONjkquUPkHCEBmSsFNkkmhtdLc8tzKPBVxlUZOAyh0skXmYOZuh1ABmLFCpnFuBZcmk04hCXMmw6tZvEuOfxZ_AG8CtjdK7-qPZtAt_y7Znj7BwWgq2TFIcdsr83zvD3fvk6UEN9Wh1HJA5iuIA-6QLJjP8bB5PwoQg7FX3H8DGNvdug |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Peripheral+neuropathy+in+non-Hodgkin%27s+lymphoma+patients+receiving+vincristine+with+and+without+aprepitant%2Ffosaprepitant&rft.jtitle=Journal+of+oncology+pharmacy+practice&rft.au=Edwards%2C+Jessi+K&rft.au=Bossaer%2C+John+B&rft.au=Lewis%2C+Paul+O&rft.au=Sant%2C+Ashley&rft.date=2020-06-01&rft.eissn=1477-092X&rft.volume=26&rft.issue=4&rft.spage=809&rft_id=info:doi/10.1177%2F1078155219870840&rft_id=info%3Apmid%2F31446866&rft_id=info%3Apmid%2F31446866&rft.externalDocID=31446866 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-092X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-092X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-092X&client=summon |